A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation

NCT00214266 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Renal Transplantation

Interventions

DRUG: Campath 1H®, Rituximab, mycophenolate mofetil

Sponsor

University of Wisconsin, Madison